MedTrace Logo

The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers

NCT04297618 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-05-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study to evaluate changes in comfort and dryness in symptomatic contact lens (CL) wearers after using Xiidra (lifitegrast 5.0% ophthalmic solution) for 12 weeks.

Conditions

  • Dry Eye

Interventions

DRUG

Xiidra

Xiidra (lifitegrast 5% ophthalmic solution)

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Waterloo

    lead OTHER

Principal Investigators

  • Lyndon Jones, PhD, FCOptom · Centre for Ocular Research & Education

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2024-04-18
Completion
2024-04-18
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04297618 on ClinicalTrials.gov